Next-Generation Sequencing Services

NGS offers a precise, high-throughput approach to analyzing genetic material at both scale and speed, supporting biomarker discovery, patient stratification, and therapeutic development.  

It has numerous translational and clinical applications, including:  

• Whole genome, whole exome, RNA, and cfDNA sequencing  
• Mutation and copy number variation (CNV) analysis  
• Fusion detection  
• Drug resistance and interaction studies 
• Tumor profiling and TCR/BCR sequencing of the immune repertoire 
• Pharmacogenetics 
• MRD and early detection 
• Spatial transcriptomics 

NGS is a core component of our comprehensive genomic service offerings. CellCarta’s NGS services are powered by a suite of high-performance sequencing platforms, including NovaSeq X Plus, NovaSeq 6000, NextSeq 550Dx, and MiSeqDx.  

We have extensive experience working with challenging samples, and are able to provide pre-analysis processing of plasma and formalin-fixed paraffin-embedded (FFPE) tissues. Our pre-analytical services are offered both as standalones and integrated components of our workflows, and include various extraction kits and quantification methods. 

With consistent cross validated instrumentation and processes in facilities across North America and Europe, we offer seamless global support, making it easy to scale projects across regions without compromising consistency or quality. 

Contact us to discover how we can support your NGS project 

We offer a selection of targeted NGS panels to support patient selection, including:  

• oncoReveal® CDx Pan-Cancer Solid Tumor IVD/FDA Assay from Pillar Biosciences: a 103 amplicon DNA panel for FFPE samples from a range of solid tumor types
•  TruSight Oncology Comprehensive (TSO Comp) assay by Illumina: an in vitro diagnostic assay to detect variants in 517 genes, including single nucleotide variants, multinucleotide variants, insertions, deletions and gene amplifications from DNA, and gene fusions and splice variants from RNA in FFPE tumor tissue
• Human leucocyte antigen (HLA) typing: high-quality, rapid sequencing of HLA genes at greater accuracy than Sanger sequencing  

To ensure each assay meets the needs of your specific study, we apply our own tier-based validation system, allowing us to tailor validation levels accordingly.  

CellCarta offers a wide portfolio of commercial NGS assays, available for easy, rapid implementation across a range of clinical and translational applications.  

Available assays include:  

• Illumina TruSeq RNA Exome 
• Illumina RNA prep with Enrichment (L) Tagmentation Kit 
• Illumina TruSight Oncology 500 High-Throughput 
• Illumina TruSight Oncology 500 ctDNA v2   
• Illumina TruSight Oncology Comprehensive 
• 10x Genomics Chromium 
• Twist Comprehensive Exome Panel (WES) 
• HLA typing (HLA-A, -B, -C, DRB1, -DQB1 & DPB1) 
• Pillar Biosciences oncoReveal® CDx Pan-Cancer Solid Tumor IVD 
• Pillar Biosciences oncoReveal® Essential LBx  
• Pillar Biosciences oncoReveal® Fusion LBx 

We also offer custom panel development for both mutation detection and gene expression.  

Additionally, our next-generation sequencing services are fully scalable, supporting everything from small, targeted panels to large biomarker panels, from small to largescale studies. 

Discover our full list of genomic assays here

CellCarta’s dedicated data science team provides detailed analysis and interpretation of NGS data to deliver in-depth insights for your studies. 

Our Illumina workflows are analyzed using Illumina Connected Analytics (ICA) software—a secure, cloud-based bioinformatics data platform that allows for pipeline customization and can support operations at any scale.  

We enhance the analytical capabilities of standard pipelines such as 10x Chromium and WES, and also provide custom computational pipeline development for advanced applications including RNA analysis and immune profiling. We can also integrate insights across our other flagship services, including IHC, proteomics and FISH.

See how our custom RNA-Seq pipeline was used to accurately predict immune checkpoint inhibitor response in our recent case study.

Discover how CellCarta’s next-generation sequencing services can support your next study. 

Contact us